Circulating tumor DNA (ctDNA) is a type of DNA produced by malignant and tumor cells that spread throughout the body. This occurs when a tumor grows and cells die, only to be replaced by a new one, releasing the dead cells into the bloodstream. This DNA are commonly found in leiomyosarcoma patients. Urine, saliva, stool, and cerebrospinal fluid all contain this DNA.
Top Companies: Vermillion, Inc., Abnova Corporation., Adaptive Biotechnology, Inivata Ltd, Biocept, Inc., QIAGEN, SAGA Diagnostics AB, RainDance Technologies, Inc, GUARDANT HEALTH, INC., Veracyte, Inc, FOUNDATION MEDICINE, INC, Trovagene, OncoCyte, iCellate AB, Myriad Genetics, Inc
Standard tissue biopsy DNA, which only examines a small portion of the tumor, ctDNA provides an impartial picture of all mutations throughout the patient’s overall tumor burden, thus lifting the growth of the circulating tumor DNA (ctDNA).
𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐆𝐫𝐚𝐛 𝐃𝐞𝐭𝐚𝐢𝐥𝐞𝐝 𝐏𝐃𝐅@ https://www.360marketupdates.com/enquiry/request-sample/20638487&piyush
Additionally, ctDNA testing can be utilized with other multi-omic biomarkers to improve early detection. Early detection proteins (such as CA-125), epigenetic markers, circulating tumor RNA, nucleosomes, exosomes, and related immunological markers, for instance, may all be included in tests. Many firms are presently competing to create a commercially viable ctDNA-based early cancer detection tool.
Application
- Routine Screening
- Patient Work Up
- Early-Stage Disease
- Late Stage/Metastatic Disease
End-Users
- Hospitals
- Research Laboratories
- Academia
- Research Centers
#testing #hospitals #circulating #tumor #dna #rna #ngs #nextgenerationsequencing #cell #biotechnology #biotech #microbiology